0407 Fibrogen
BioCentury & Getty Images

Product Development

FibroGen falters ahead of roxadustat’s FDA review

Apr 8, 2021 | 12:03 AM GMT

Revised cardiovascular safety data for FibroGen’s roxadustat sent the company’s shares down $14.75 (43%) to $19.88 on Wednesday as investors digested its implications for the

Read the full 445 word article

How to gain access

Continue reading with a
two-week free trial.